Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

KETOCONAZOLE

All products: general benefit

Other products in the same Health Canada class (D01A, D01AC) — coverage varies; not interchangeable

  • Clotrimazole (Clotrimaderm): general benefit, Not a benefit
  • Miconazole nitrate (Micatin): general benefit
  • Betamethasone dipropionate + clotrimazole (Lotriderm Cream): not a benefit
  • Nystatin (Mycostatin): general benefit, Not a benefit
  • Terbinafine (Lamisil): general benefit
  • Ciclopirox (Penlac): not a benefit

Ketoderm · DIN 02245662 · 2% · Cr

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ketoderm · DIN 02245662 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2004-04-06 Health Canada: Marketed since 2004-03-19 · brand KETODERM CREAM 2% · ATC D01AC08 KETOCONAZOLE · form Cream · route Topical · ingredients KETOCONAZOLE 2 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ketoderm: Formulary list price $0.4043/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4043 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69762 · Verify on the e-Formulary ↗ (DIN 02245662)

Source record
DIN 02245662: Ketoderm Raw flags: sec3=Y Item: 840408034; group id 821; item number 2003; lccId None; manufacturer id TAR Source form: Cr; strength: 2% Recorded listing: General benefit Source prices (unrounded): $0.4043; ministry $0.4043 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245662 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69762
Interchangeable products
Nizoral · DIN 00703974 · not recorded
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:04:08 Fungicides) and how they are covered

Matched class: 84:04:08 Fungicides

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: MICONAZOLE NITRATE, TERBINAFINE HCL Some products covered without a code (check the product listing): CLOTRIMAZOLE, NYSTATIN, TERCONAZOLE 84:04:08 Fungicides

CLOTRIMAZOLE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 10mg/g, 500mg & 1%, 20mg/g · Cr, Tab & Cr, Vag Cr-App

MICONAZOLE NITRATE

· 1 products · General benefit · strengths: 2% · Cr

CLOTRIMAZOLE & BETAMETHASONE DIPROPIONATE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1% w/w & 0.05% w/w · Top Cr

NYSTATIN

· 7 products · Listed, not a benefit (3), General benefit (4) · strengths: 100000U/g, 25000U/g · Cr, Oint, Vag Cr

TERBINAFINE HCL

· 1 products · General benefit · strengths: 1% · Cr

CICLOPIROX

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 8% W/W · Top Sol

TERCONAZOLE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.4% · Vag Cr

FLUCONAZOLE

· 8 products · Limited Use, codes 235 · strengths: 150mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:08
Full class listing Related classes: 84:04:04 Antibiotics, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS For the treatment of serious or life-threatening systemic fungal infections in normal, predisposed or immunocompromised patients where alternate therapy is considered inappropriate or has been unsuccessful: systemic candidiasis, chronic mucocutaneous candidiasis, coccidioidomycosis and paracoccidioidomycosis, histoplasmosis and chromomycosis. Its use may also be considered in the treatment of severe, recalcitrant dermatophytoses unresponsive to other forms of therapy. The type of organism responsible for the infection should be identified; however, therapy may be initiated prior to obtaining these results, when clinically warranted. 1 Note: The treatment of fungal infections of the CNS is not recommended; ketoconazole penetrates poorly into the CNS. https://pdf.hres.ca/dpd_pm/00024529.PDF PM date: not printed or not captured Source product: TEVA-KETOCONAZOLE; DIN 02231061; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.